Kamada (KMDA) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed Kamada (KMDA) over the past year, gaining 119.7% versus a gain of 14.7%. Over five years, KMDA leads with a +22.7% price change compared with -52.0% for STTK. Shattuck Labs is the larger company by market cap ($454.2 million vs $446.8 million), about 1.0 times the size, while Kamada is growing revenue faster (+12.1% vs -82.5%).
Kamada pays a dividend yielding 7.24%, while Shattuck Labs does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus -4880.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KMDA | STTK |
|---|---|---|
| Share price | $7.74 | $4.46 |
| Market cap | $446.85M | $454.22M |
| 1-day change | -1.15% | -1.98% |
| YTD return | +9.63% | +22.19% |
| 1-year return | +14.67% | +119.70% |
| 5-year return | +22.66% | -51.99% |
| P/E ratio (TTM) | 20.37 | — |
| Forward P/E | 13.34 | — |
| EPS (TTM) | $0.38 | $-0.47 |
| Dividend yield | 7.24% | 0.00% |
| Annual dividend | $0.56 | $0.00 |
| Revenue (latest FY) | $180.46M | $1.00M |
| Revenue growth (YoY) | +12.12% | -82.52% |
| Net income (latest FY) | $20.20M | $-48.81M |
| Gross margin | 42.34% | — |
| Operating margin | 14.54% | -5150.80% |
| Net margin | 11.19% | -4880.90% |
| 52-week high | $9.35 | $8.33 |
| 52-week low | $6.63 | $1.93 |
| Distance from 52-week high | -17.22% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.65% | +245.29% |
| Average volume | 121.87K | 1.20M |
| Shares outstanding | 57.73M | 101.84M |
| Employees | 462 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed KMDA by 105.0 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
- Kamada is more profitable, keeping 11.2 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
- Kamada grew revenue faster in its latest fiscal year (+12.12% vs -82.52%).
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
KMDA vs STTK FAQ
Which is bigger, Kamada or Shattuck Labs?
Shattuck Labs (STTK) is larger, with a market capitalization of $454.22M compared with $446.85M for Kamada (KMDA).
Which stock has performed better over the past year, KMDA or STTK?
STTK returned +119.70% over the past 12 months, compared with +14.67% for KMDA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Kamada or Shattuck Labs?
Kamada pays a dividend yielding 7.24%, while Shattuck Labs does not currently pay a regular dividend.
Are Kamada and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.